TSE:4536Pharmaceuticals
Santen Pharmaceutical (TSE:4536) EPS Jump Reinforces Profitable But Slower Growth Narrative
Setting the scene on Santen Pharmaceutical's FY 2026 results
Santen Pharmaceutical (TSE:4536) has reported a solid finish to FY 2026, with fourth quarter revenue of ¥80.9b and basic EPS of ¥48.36, alongside net income excluding extra items of ¥15,553m. Over the last two reported fourth quarters, revenue has moved from ¥77.2b in FY 2025 to ¥80.9b in FY 2026, while basic EPS shifted from ¥25.74 to ¥48.36 and trailing 12 month EPS stood at ¥114.06 on revenue of ¥291.6b, providing a reference...